Assolid

Quick links to important sections

Assolid

Treatment option: Asthma, Bronchospasm

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Assolid

Property Description
Active ingredient Flunisolide
Form Nasal solution (Metered-dose spray) or Inhalation aerosol
Pharmacological class Corticosteroid (Glucocorticoid)
General purpose Anti-inflammatory action; Prophylactic management of swelling
Origin Synthetic

Assolid: Definition and Pharmacological Classification

Assolid is a trade name for a medicine containing the active ingredient Flunisolide, which is classified as a powerful synthetic corticosteroid. This substance belongs specifically to the glucocorticoid pharmacological class, meaning it is a man-made compound designed to mimic the action of natural adrenal hormones in the body. The function of Flunisolide is its potent anti-inflammatory action, which is key to controlling inflammation. Assolid is distinguished as a prescription-only medication (Rx status), reinforcing its professional management requirements. It is a single-active-ingredient product, focusing the entire action on the properties of the Flunisolide molecule, immediately identifying its primary function as a targeted anti-inflammatory steroid.


Composition and Targeted Delivery Form

The product's identity is largely defined by its form: Assolid is typically supplied as a sterile nasal solution for intranasal application or an inhalation aerosol for oral inhalation. The nasal form is designed as a metered-dose spray where the Flunisolide is dissolved in an aqueous base (a water-based vehicle). This specific format allows the medication to be delivered directly to the inflamed mucosal surfaces of the nose or airways, ensuring a localized and precise distribution of the synthetic anti-inflammatory compound. The intranasal route is clinically recognized for maximizing the drug’s benefit locally while limiting distribution throughout the rest of the body. This targeted delivery system is a key feature, allowing for effective management in both adult and pediatric patient groups (specifically children aged six and older for certain forms).


Primary Function and General Anti-Inflammatory Purpose

The general purpose of Flunisolide (Assolid) is to control and suppress inflammation associated with persistent allergic or non-infectious inflammatory processes. It acts as a powerful immune modifier by fundamentally intervening in the cascade that triggers swelling, redness, and irritation in the body's tissues. Flunisolide effectively blocks the release of numerous inflammatory chemicals, demonstrating its unique anti-inflammatory efficiency. By exerting its strong anti-inflammatory action, the medicine helps to reduce chronic swelling and stabilize sensitive tissue. This core function is utilized in the prophylactic management of conditions driven by persistent inflammation, such as seasonal allergic reactions.

Regulatory References

  1. Flunisolide Nasal Solution Label (NIH/DailyMed)

What side effects are possible with Assolid?

Possible Side Effects and Safety Information

The safety profile of Assolid (Flunisolide), a synthetic corticosteroid, is primarily characterized by local adverse reactions due to its topical administration, as detailed in official regulatory documents (FDA/SmPC).


Documented Adverse Reactions

Adverse effects are classified by the physiological system they affect, according to regulatory standards.

Classification Examples of Documented Reactions
Highly Frequent Nasal burning/stinging, pharyngitis, aftertaste, headache
Common Epistaxis (nosebleeds), nasal dryness, increased cough, nausea
System-Organ Class Respiratory (local irritation), Nervous System (dizziness), Infections (localized Candida infection)

Serious Safety Considerations

While systemic exposure is typically low, the profile includes serious risks associated with the corticosteroid class, particularly with prolonged use.

  • HPA Axis Suppression: The potential for adrenal suppression exists, especially upon transfer from systemic oral steroids, requiring monitoring.
  • Tissue Damage: Rare reports of nasal septal perforation and ulceration have been documented.
  • Ocular Effects: Long-term use is associated with the risk of cataracts and glaucoma (increased intraocular pressure).

Population and Duration Patterns

Official labeling defines specific constraints and patterns:

  • Pediatric Use: Regulatory documents note the potential for a reduction in growth velocity; growth monitoring is advised during extended treatment.
  • Time-Related Pattern: Systemic risks (e.g., HPA suppression, ocular effects) are directly linked to prolonged use and/or dosages exceeding recommended levels.
  • Safety Restriction: Use is contraindicated or requires caution in the presence of an untreated localized nasal infection or in patients with recent nasal trauma or surgery, due to the steroid's documented inhibitory effect on wound healing.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documents define the overdose profile for Flunisolide (Assolid) primarily around the physiological consequences of Systemic Glucocorticoid Excess rather than acute toxicology.

Documented Overdose Manifestations

Overdose, which results from the use of excessive doses or prolonged high exposure, may lead to clinical manifestations of hypercorticism [FDA Prescribing Information]. The primary concern is functional suppression of the Hypothalamic-Pituitary-Adrenal (HPA) axis [NIH DailyMed]. This condition, known as adrenal suppression, is the basis for the most severe documented outcome: the risk of Acute Adrenal Insufficiency, particularly when patients are subjected to stress or during withdrawal from systemic corticosteroids.

Regulator-Mandated Emergency Actions

If there is known or suspected use of an excessive dose of Assolid, official guidance requires the patient to seek immediate medical attention. Patients must call 911 or contact a Poison Control center [MedlinePlus].

In cases where signs of excess corticosteroid effect are confirmed, the regulatory documents mandate careful monitoring of HPA function. Management is typically supportive as there is no specific antidote listed. If manifestations of hypercorticism or adrenal suppression appear, the medication should be discontinued slowly to mitigate withdrawal risk [FDA Prescribing Information]. Pediatric patients are a specific consideration, as the risk of HPA suppression is heightened with excessive dosage in this population [NIH DailyMed].

Therapeutic Uses of Assolid

What Assolid Treats: Main Uses and Benefits

This medication is generally used across the respiratory system to manage conditions driven by chronic inflammation. Assolid is commonly used for managing conditions characterized by periods of heightened symptoms, including seasonal allergic rhinitis, perennial rhinitis, and chronic asthma.

It is primarily applied across domains where additional symptomatic support is needed to address symptom clusters that interfere with daily functioning. The medication is considered relevant for easing respiratory manifestations such as persistent nasal congestion, excessive rhinorrhea, sneezing, nasal itching, wheezing, chronic coughing, and chest tightness.

The treatment contributes to improved comfort during periods of heightened symptoms, supporting the patient during difficult episodes. For patients with asthma, it may assist with reducing the need for systemic oral steroids, applied across domains where additional symptomatic support is needed.


Quick Fact: Symptomatic Support Assolid is commonly used to help with managing symptoms related to inflammatory or irritative states in the nasal passages and airways.


Regulatory References

  1. NIH MedlinePlus overview of Flunisolide

Eligibility and Restrictions for Use

Assolid (Flunisolide) use is strictly defined by regulatory guidelines concerning patient population and specific health status.

Absolute Contraindications

Use of Assolid is absolutely contraindicated in patients with a documented hypersensitivity or allergy to Flunisolide or any component of the medication. The medication must not be used for primary treatment of status asthmaticus or acute episodes of asthma (inhalation forms). The nasal solution is contraindicated if an untreated localized infection is present in the nasal mucosa.

Age and Physiological Restrictions

Children younger than 6 years of age are generally not eligible, as the safety and efficacy of Assolid have not been established in this group. Use in all pediatric patients requires growth monitoring due to the potential for a reduction in growth velocity.

Use in pregnant women is assigned FDA Category C, meaning it should only be used if the potential benefit justifies the potential risk. Caution is recommended during lactation as it is unknown if the drug passes into breast milk.

Conditional Use and Precautions

Assolid should be used with caution and under close professional supervision in patients with tuberculosis, ocular herpes simplex, or other untreated fungal, bacterial, or systemic viral infections. Additionally, patients recovering from recent nasal surgery, trauma, or septal ulcers are generally restricted until complete healing has occurred.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The official regulatory profile for Flunisolide (Assolid) documents specific constraints regarding co-administration with certain substance categories. This information details required patient monitoring and classified combination risks, based strictly on government drug labels.

Official Interaction Statements

Classification Interacting Substance/Condition Regulatory Constraint/Outcome
Contraindicated Hypersensitivity to any ingredient Formal prohibition of use
Pharmacodynamic Systemic Corticosteroids (e.g., Prednisone) Risk of additive HPA axis suppression
Pharmacokinetic Strong CYP3A4 Inhibitors (e.g., Ritonavir, Itraconazole) Potential for increased systemic exposure of Flunisolide
Population Note Patients transitioning from systemic steroids Requires careful monitoring for acute adrenal insufficiency

The primary concern noted in official documentation is the Pharmacodynamic Interaction with other systemic glucocorticoids, which raises the likelihood of HPA axis suppression. Additionally, co-administration with strong inhibitors of the CYP3A4 metabolic enzyme may lead to a Pharmacokinetic Interaction, increasing the concentration of Flunisolide in the bloodstream. The regulatory information requires specific attention and monitoring for patients who are transitioning from long-term systemic steroid therapy, due to the inherent risk of withdrawal or insufficiency related to the change in drug exposure.

Mechanism of Action

How Assolid Works

Assolid (Flunisolide) operates through a genomic mechanism that fundamentally alters the transcription profile of cells within the respiratory mucosa, leading to the modulation of inflammatory signaling. The drug's effect begins as a direct agonist of the cytoplasmic Glucocorticoid Receptor (GR). Once activated, the Flunisolide-GR complex translocates to the cell nucleus to influence the cell's genetic code. This molecular cascade involves both enhancing anti-inflammatory genes (transactivation) and suppressing the genes responsible for generating inflammatory proteins by inhibiting transcription factors like NF-κB (transrepression).

This direct action on the nucleus ultimately causes the indirect inhibition of critical enzymes, notably Phospholipase A₂ (PLA₂). This suppression of PLA₂ interrupts the Arachidonic Acid Cascade, resulting in a reduction of key pro-inflammatory mediators, including prostaglandins and leukotrienes. The molecular changes lead to decreased blood vessel permeability and the inhibition of immune cell infiltration, particularly eosinophils, into the mucosal tissue, resulting in decreased local tissue edema and modulation of the inflammatory response kinetics.

Dosage and Administration Information

Instructions for Using Assolid

Assolid is administered via the Oral route (tablets or suspension) or by Intravenous (IV) Infusion. No dose adjustment is required when switching between the oral and intravenous forms of the drug, as its oral bioavailability is near 100%.

Dosing and Frequency

The treatment duration is typically 10 to 28 consecutive days, as determined by the physician and infection type, but should not exceed 28 days based on controlled clinical trial data.

Age Group Dose and Frequency (Standard) Route of Administration
Adults and Adolescents (ge12 yrs) 600 mg every 12 hours (Twice daily) Oral or IV Infusion
Pediatric Patients (<12 yrs) 10 mg/kg every 8 hours (Three times daily) Oral or IV Infusion

For patients undergoing hemodialysis, the dose should be administered after the dialysis session is completed.

Preparation and Administration

  • Oral Tablets: Swallow the film-coated tablet whole with water. Do not crush or chew it. It may be taken with or without food.
  • Oral Suspension: Gently mix the bottle by inverting it three to five times before each dose. Do not shake vigorously.
  • IV Infusion: The injection is a ready-to-use solution that must be administered as an IV infusion over a period of 30 to 120 minutes. Do not introduce additives to the solution or use it in a series connection with other drugs. If co-administering with another medication, each drug must be given separately.

Missed Dose

If a dose is missed, it should be taken as soon as possible. However, if it is almost time for the next scheduled dose, skip the missed dose and resume the regular dosing schedule. Do not take a double dose to compensate for the one that was missed.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Assolid

The following summary outlines the types of clinical studies that have been conducted on Assolid (Flunisolide) for conditions where its use was studied. This information is intended to provide context on the available research and is not a substitute for clinical advice or individual medical guidance.

Evidence for Use in Seasonal Allergic Rhinitis (SAR)

Research into the use of this medicine typically involves short-term, placebo-controlled Randomized Controlled Trials (RCTs) and systematic reviews. These studies explored how symptoms change over time and during periods of increased symptom activity. The primary focus of these trials was to monitor patient-reported outcomes related to symptom intensity, including measurements of common nasal symptoms like congestion, sneezing, and itching. Studies included populations of adults and children (aged 6 and older).

Evidence for Use in Perennial Rhinitis (PR)

Clinical evaluation for conditions characterized by fluctuating manifestations like perennial rhinitis was conducted through intermediate-term research, including double-blind trials. These studies focused on assessing outcomes over a sustained duration in the research setting for chronic, year-round nasal symptoms. Research examined the collection of data over several months, monitoring outcomes related to patient-reported discomfort. Findings were mixed across studies, and evidence for these conditions remains limited and heterogeneous due to the differing causes of perennial rhinitis in the populations studied.

Evidence for Use as Maintenance Therapy for Chronic Asthma

The inhaled form of Assolid was evaluated in controlled clinical trials and comprehensive reviews relevant in research contexts involving fluctuating or unstable symptoms of persistent asthma. These studies monitored outcomes related to functional imbalance, specifically looking at changes in lung function test results, such as FEV1 and PEFR. Research describes patterns monitored in relation to the reported use of supplemental medications during the study period. Study results reflect the specific conditions under which they were conducted to evaluate outcomes, as opposed to trials focused on acute symptom changes.

What is Still Uncertain in the Research Landscape

The research evidence for Assolid is primarily derived from studies with follow-up durations that were limited, typically lasting a few weeks to several months. Therefore, long-term effects are not fully established, and there is limited information regarding chronic administration of the medicine in study settings over many years. Comparative evidence is lacking against some newer treatment options, and data for certain subgroups (e.g., infants, severe comorbidities) remain insufficient.

Key Studies & References

  1. Flunisolide Nasal Spray: MedlinePlus Drug Information (Authoritative overview used for indications and age ranges)

Frequently Asked Questions (FAQ)

Common questions about Assolid (FAQ)


Q: How long does it typically take for Assolid to start working?

Studies indicate that an improvement in symptoms is usually noticeable within a few days of starting regular use of Assolid. However, the medicine may require one to two weeks of consistent use to achieve its maximum benefit. The product is not intended for acute relief.


Q: Do people usually take Assolid long-term or short-term?

Official information describes that the typical duration of treatment is short-term, often ranging from 10 to 28 consecutive days, depending on the patient's condition. While the medicine may be used for longer periods under professional management, official product information suggests a review if no significant improvement is seen after approximately three weeks.


Q: What happens if I miss a day of taking Assolid?

If a dose is missed, regulatory information advises taking it as soon as possible. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped, and the regular schedule should be resumed. Regulatory guidelines caution against taking a double dose to compensate, noting that Assolid requires regular use for therapeutic effectiveness.


Q: Why do official documents say Assolid is not recommended for certain patients?

Official documents outline precautions regarding use in certain patient groups to ensure safety. For example, use is cautioned in children because of the potential for a reduction in growth velocity; therefore, growth monitoring is advised. Additionally, because the medicine is a steroid that can inhibit wound healing, it is generally not recommended for patients with recent nasal trauma or active, untreated local infections.


Q: Do the side effects of Assolid usually go away over time?

Official patient information notes that common, localized side effects, such as nasal burning, stinging, or headache, are possible when starting the medicine. These types of temporary side effects often go away after a short period. If symptoms like irritation or bleeding persist or worsen, official labeling suggests professional evaluation.


Q: Is Assolid the same type of medicine as [similar drug name]?

Assolid, which contains the active ingredient Flunisolide, is classified as a synthetic corticosteroid (glucocorticoid) and is used as an anti-inflammatory. While other drugs may belong to the same pharmacological class and treat similar conditions, they are chemically distinct medicines with their own regulatory profiles, including specific dosages and administration requirements.


Q: Can Assolid cause problems with sleep?

Sleep problems or insomnia are not listed as a common or frequent adverse reaction in official drug labeling for Assolid. The most commonly reported side effects are localized effects related to its use as a nasal spray or inhaler. If unusual or persistent sleep changes occur, regulatory guidance suggests consulting a healthcare professional.


Q: Is it okay to take Assolid with vitamins or supplements?

Official labeling specifically lists required monitoring for interactions with certain strong CYP3A4 inhibitors and systemic corticosteroids. Since regulatory documents cannot list every available vitamin or supplement, patients are routinely advised to inform their healthcare professional of all products they are taking, including herbal remedies and supplements.


Q: Is Assolid safe for use in older adults?

Clinical trials generally included younger subjects, so no definitive difference in effectiveness or safety has been established for patients 65 years of age and older. Use in older adults is often managed with caution due to the potential for age-related changes, such as decreased kidney or liver function, which can influence how the drug is processed by the body.


Q: Is it true that Assolid can affect my weight?

Weight gain is not listed as a common side effect in official labeling for Assolid when used at the recommended doses. However, using doses that are higher than recommended over a long period may lead to an over-exposure to steroids, which is known to be associated with systemic effects like weight changes.


Q: Can Assolid be used by teenagers or children?

Official documents indicate that Assolid is generally suitable for use in pediatric patients aged 6 years and older. However, the medicine's safety and effectiveness have not been established in children younger than 6 years of age. For all children and adolescents on long-term treatment, growth monitoring is advised.


Q: Is it possible to become dependent on Assolid?

Assolid is a corticosteroid, and official documents note a potential risk of HPA axis suppression with prolonged or excessive use, particularly if transitioning from systemic steroids. This condition requires careful professional monitoring and withdrawal to prevent adrenal insufficiency. The medicine is not formally classified under controlled substance schedules.


Q: What should I know about driving while taking Assolid?

Official labeling lists dizziness as a possible, but not frequent, adverse reaction. Official labeling advises using caution when driving or operating machinery if dizziness or other effects are experienced.


Q: What is the general difference between Assolid and generic versions?

Assolid is a trade name for a medicine containing the active ingredient Flunisolide. A generic version must contain the identical active ingredient at the same strength, dosage form, and route of administration. Regulatory bodies require generic versions to meet the same strict standards for quality and performance as the original brand product.


Q: Can Assolid make me feel tired or drowsy?

Drowsiness or unusual fatigue is not listed as a common or frequent side effect in the official drug labeling for Assolid at recommended doses. Regulatory warnings do note that fatigue and tiredness can be signs of adrenal insufficiency, a condition that may occur if transitioning from systemic steroids.


Q: How does Assolid compare to older medications for the same condition?

Regulatory documents classify Assolid as a synthetic corticosteroid that provides a potent anti-inflammatory action by influencing cellular genetics (a genomic mechanism). While official sources define the medicine’s pharmacological action, they do not make comparative claims regarding whether it is superior to older or newer treatment options.


Q: Are there known risks for people with liver or kidney problems taking Assolid?

The medicine is primarily metabolized, or broken down, by the liver. While the nasal spray form is generally associated with low systemic exposure, older adults are monitored for potential decreased function in the liver or kidneys which could affect the clearance of the drug from the body.


Q: What is the typical duration of Assolid's effect after a dose?

Pharmacokinetic data from official sources indicate that the medicine has a plasma half-life of 1 to 2 hours. The half-life refers to the time it takes for the concentration of the drug in the bloodstream to be reduced by half.


Q: Do I need any special monitoring or blood tests while on Assolid?

Growth monitoring (using measurements like stadiometry) is required for all pediatric patients on long-term treatment. Additionally, patients who have risk factors for bone loss or who are at risk for hormonal imbalance may be periodically monitored via blood tests or other assessments.


Q: Is there a certain time of day that is best for taking Assolid?

Official dosing instructs taking the medicine at regular intervals throughout the day (e.g., every 12 hours) to maintain its therapeutic effect. The official labeling does not specify a particular time, such as morning or evening, as being inherently better for taking the dose.


Q: Does Assolid interact with herbal remedies like St. John's Wort?

Official labeling warns against combining Assolid with other strong CYP3A4 inhibitors because this could increase the medicine's concentration in the body. While specific herbal remedies are not listed, official documents recommend caution with any strong herbal or supplement that can affect the way the body metabolizes drugs.


Q: Is there any research on Assolid's long-term safety?

The safety profile notes that long-term effects over many years are not fully established because the follow-up periods in key clinical trials were often limited to a few weeks or months. For this reason, the need for pediatric growth monitoring and the risk of ocular effects are noted when Assolid is used over extended periods.


Q: Is it possible to take too much Assolid accidentally?

Yes, taking doses that are higher than recommended over a short period may lead to a temporary suppression of HPA function (a hormonal imbalance). Regulatory documents state this condition is typically self-limiting. The greater risk is associated with prolonged use of excessive doses, which can lead to more serious, systemic steroid side effects.


Q: What does the research say about the success rates of Assolid?

Clinical trials found that the medicine demonstrated efficacy in reducing symptoms in patient groups studied for conditions like rhinitis or asthma. Success was determined by monitoring specific patient-reported outcomes for symptoms (e.g., stuffy nose, sneezing) and objective measurements of lung function, such as FEV1.


Q: Can Assolid be used with common cold and flu medications?

Official drug labels are generally limited to specific, known drug-drug interactions. It is noted in some patient information that other medications, such as nasal decongestants, may be necessary when starting treatment, suggesting that some common cold medications may be used concurrently. Regulatory practice requires all co-administration to be professionally reviewed to avoid potential interactions.


Q: What kind of studies led to the approval of Assolid?

The drug's approval was based on evidence from controlled clinical studies, including placebo-controlled Randomized Controlled Trials (RCTs). These studies were conducted across relevant patient groups to assess the medicine’s ability to reduce symptoms for its specific indications.


Q: Does Assolid cause any problems with vision?

The long-term administration of corticosteroids is officially associated with risks of cataracts and glaucoma (increased pressure in the eye). Patients, especially those using the medicine long-term or those with pre-existing vision concerns, should be monitored closely for ocular effects.


Q: How is the benefit of Assolid measured in clinical trials?

The benefit in clinical trials was measured using a combination of methods. This included monitoring patient-reported outcomes, where patients scored the severity of their symptoms, and using objective measurements for lung function, such as the Forced Expiratory Volume 1 (FEV1).

How should Assolid be stored and disposed of?

The official labeling for Assolid (Flunisolide) requires strict adherence to temperature and handling constraints to maintain product integrity and safety.

Storage Requirements

  • Temperature: Store at Controlled Room Temperature, generally 15 C to 30 C (59 F to 86 F). The product must be protected from heat and light and must not be frozen.
  • Container and Stability: Keep the medicine in its original container with the cap tightly closed. The metered-dose unit must be discarded after the specified number of sprays or 3 months after first use, whichever comes first.
  • Child Safety: Assolid must be stored out of the reach and sight of children.

Disposal Instructions

  • Method: Unused or expired medication should be discarded using a drug take-back program whenever possible.
  • Household Trash: If a take-back program is unavailable, mix the medicine with an unappealing substance, seal it in a container, and dispose of it in the trash. Do not flush Assolid down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Assolid found in:

A-Z Index: